Browse PDE11A

Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol
Domain PF01590 GAF domain
PF00233 3'5'-cyclic nucleotide phosphodiesterase
Function

Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP. Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively.

> Gene Ontology
 
Biological Process GO:0006195 purine nucleotide catabolic process
GO:0006198 cAMP catabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009154 purine ribonucleotide catabolic process
GO:0009166 nucleotide catabolic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009214 cyclic nucleotide catabolic process
GO:0009261 ribonucleotide catabolic process
GO:0019439 aromatic compound catabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046058 cAMP metabolic process
GO:0046068 cGMP metabolic process
GO:0046069 cGMP catabolic process
GO:0046434 organophosphate catabolic process
GO:0046700 heterocycle catabolic process
GO:0072523 purine-containing compound catabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901292 nucleoside phosphate catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0004112 cyclic-nucleotide phosphodiesterase activity
GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity
GO:0004115 3',5'-cyclic-AMP phosphodiesterase activity
GO:0004118 cGMP-stimulated cyclic-nucleotide phosphodiesterase activity
GO:0008081 phosphoric diester hydrolase activity
GO:0019001 guanyl nucleotide binding
GO:0030551 cyclic nucleotide binding
GO:0030552 cAMP binding
GO:0030553 cGMP binding
GO:0032561 guanyl ribonucleotide binding
GO:0042578 phosphoric ester hydrolase activity
GO:0047555 3',5'-cyclic-GMP phosphodiesterase activity
Cellular Component GO:0043025 neuronal cell body
GO:0043204 perikaryon
GO:0044297 cell body
> KEGG and Reactome Pathway
 
KEGG hsa00230 Purine metabolism
Reactome R-HSA-418555: G alpha (s) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-109582: Hemostasis
R-HSA-392154: Nitric oxide stimulates guanylate cyclase
R-HSA-418346: Platelet homeostasis
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-418457: cGMP effects
Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PDE11A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PDE11A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PDE11A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1160.72
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8310.164
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4110.385
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0340.959
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6350.695
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7340.68
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1240.867
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4060.703
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.220.845
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1630.71
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0830.887
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8420.00404
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PDE11A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PDE11A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PDE11A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PDE11A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PDE11A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PDE11A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PDE11A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPDE11A
Namephosphodiesterase 11A
Aliases PPNAD2; cAMP and cGMP cyclic nucleotide phosphodiesterase 11A; cAMP and cGMP phosphodiesterase 11A; Dual 3', ......
Chromosomal Location2q31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PDE11A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PDE11A.
ID Name Drug Type Targets #Targets
DB00201CaffeineSmall MoleculeADORA1, ADORA2A, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, ......33
DB00820TadalafilSmall MoleculePDE11A, PDE5A2
DB09283TrapidilSmall MoleculePDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, P ......21